Cargando…

Impact of Transfusion on Cancer Growth and Outcome

For many years, transfusion of allogeneic red blood cells, platelet concentrates, and plasma units has been part of the standard therapeutic arsenal used along the surgical and nonsurgical treatment of patients with malignancies. Although the benefits of these blood products are not a matter of deba...

Descripción completa

Detalles Bibliográficos
Autores principales: Goubran, Hadi A., Elemary, Mohamed, Radosevich, Miryana, Seghatchian, Jerard, El-Ekiaby, Magdy, Burnouf, Thierry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4790595/
https://www.ncbi.nlm.nih.gov/pubmed/27006592
http://dx.doi.org/10.4137/CGM.S32797
_version_ 1782421004128092160
author Goubran, Hadi A.
Elemary, Mohamed
Radosevich, Miryana
Seghatchian, Jerard
El-Ekiaby, Magdy
Burnouf, Thierry
author_facet Goubran, Hadi A.
Elemary, Mohamed
Radosevich, Miryana
Seghatchian, Jerard
El-Ekiaby, Magdy
Burnouf, Thierry
author_sort Goubran, Hadi A.
collection PubMed
description For many years, transfusion of allogeneic red blood cells, platelet concentrates, and plasma units has been part of the standard therapeutic arsenal used along the surgical and nonsurgical treatment of patients with malignancies. Although the benefits of these blood products are not a matter of debate in specific pathological conditions associated with life-threatening low blood cell counts or bleeding, increasing clinical evidence is nevertheless suggesting that deliberate transfusion of these blood components may actually lead to negative clinical outcomes by affecting patient’s immune defense, stimulating tumor growth, tethering, and dissemination. Rigorous preclinical and clinical studies are needed to dimension the clinical relevance, benefits, and risks of transfusion of blood components in cancer patients and understand the amplitude of problems. There is also a need to consider validating preparation methods of blood components for so far ignored biological markers, such as microparticles and biological response modifiers. Meanwhile, blood component transfusions should be regarded as a personalized medicine, taking into careful consideration the status and specificities of the patient, rather than as a routine hospital procedure.
format Online
Article
Text
id pubmed-4790595
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Libertas Academica
record_format MEDLINE/PubMed
spelling pubmed-47905952016-03-22 Impact of Transfusion on Cancer Growth and Outcome Goubran, Hadi A. Elemary, Mohamed Radosevich, Miryana Seghatchian, Jerard El-Ekiaby, Magdy Burnouf, Thierry Cancer Growth Metastasis Review For many years, transfusion of allogeneic red blood cells, platelet concentrates, and plasma units has been part of the standard therapeutic arsenal used along the surgical and nonsurgical treatment of patients with malignancies. Although the benefits of these blood products are not a matter of debate in specific pathological conditions associated with life-threatening low blood cell counts or bleeding, increasing clinical evidence is nevertheless suggesting that deliberate transfusion of these blood components may actually lead to negative clinical outcomes by affecting patient’s immune defense, stimulating tumor growth, tethering, and dissemination. Rigorous preclinical and clinical studies are needed to dimension the clinical relevance, benefits, and risks of transfusion of blood components in cancer patients and understand the amplitude of problems. There is also a need to consider validating preparation methods of blood components for so far ignored biological markers, such as microparticles and biological response modifiers. Meanwhile, blood component transfusions should be regarded as a personalized medicine, taking into careful consideration the status and specificities of the patient, rather than as a routine hospital procedure. Libertas Academica 2016-03-13 /pmc/articles/PMC4790595/ /pubmed/27006592 http://dx.doi.org/10.4137/CGM.S32797 Text en © 2016 the author(s), publisher and licensee Libertas Academica Ltd. This is an open-access article distributed under the terms of the Creative Commons CC-BY-NC 3.0 License.
spellingShingle Review
Goubran, Hadi A.
Elemary, Mohamed
Radosevich, Miryana
Seghatchian, Jerard
El-Ekiaby, Magdy
Burnouf, Thierry
Impact of Transfusion on Cancer Growth and Outcome
title Impact of Transfusion on Cancer Growth and Outcome
title_full Impact of Transfusion on Cancer Growth and Outcome
title_fullStr Impact of Transfusion on Cancer Growth and Outcome
title_full_unstemmed Impact of Transfusion on Cancer Growth and Outcome
title_short Impact of Transfusion on Cancer Growth and Outcome
title_sort impact of transfusion on cancer growth and outcome
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4790595/
https://www.ncbi.nlm.nih.gov/pubmed/27006592
http://dx.doi.org/10.4137/CGM.S32797
work_keys_str_mv AT goubranhadia impactoftransfusiononcancergrowthandoutcome
AT elemarymohamed impactoftransfusiononcancergrowthandoutcome
AT radosevichmiryana impactoftransfusiononcancergrowthandoutcome
AT seghatchianjerard impactoftransfusiononcancergrowthandoutcome
AT elekiabymagdy impactoftransfusiononcancergrowthandoutcome
AT burnoufthierry impactoftransfusiononcancergrowthandoutcome